Haploidentical stem cell transplantation augmented by CD45RA negative lymphocytes provides rapid engraftment and excellent tolerability

Pediatric Blood and Cancer

Volumn 62, Issue 4, 2015, Pages 666-673

  Shook, David R ^a,b   Triplett, Brandon M ^a,b   Eldridge, Paul W ^c   Kang, Guolian ^a   Srinivasan, Ashok ^a,b   Leung, Wing ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Graft versus host disease; Immunotherapy; NK cells BMT; Stem cell transplantation

Indexed keywords

CD45RA ANTIGEN; CD45 ANTIGEN;

ABDOMINAL TUMOR; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CD3+ T LYMPHOCYTE; CD45RA- T LYMPHOCYTE; CHILD; CLINICAL ARTICLE; ENGRAFTMENT; EWING SARCOMA; FEMALE; GRAFT VERSUS HOST REACTION; HAPLOIDENTICAL ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; IMMUNOLOGICAL TOLERANCE; MALE; MYELOABLATIVE CONDITIONING; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SCHOOL CHILD; T CELL DEPLETION; T LYMPHOCYTE; VEIN OCCLUSION; YOUNG ADULT; ALLOGRAFT; B LYMPHOCYTE; CLINICAL TRIAL; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOCYTE DEPLETION; METABOLISM; MULTICENTER STUDY; NEOPLASMS; PATHOLOGY; PRESCHOOL CHILD; PROCEDURES; UNRELATED DONORS;

ADOLESCENT; ADULT; ALLOGRAFTS; ANTIGENS, CD45; B-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE DEPLETION; MALE; NEOPLASMS; T-LYMPHOCYTES; UNRELATED DONORS;

EID: 84923225278     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25352     Document Type: Article

References (56)

1. Leung W, Campana D, Yang J, et al. High success of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood 2011; 118:223-230.
2. Claviez A, Canals C, Dierickx D, et al. Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: An analysis of the European Group for Blood and Marrow Transplantation. Blood 2009; 114:2060-2067.
3. Woessmann W, Peters C, Lenhard M, et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents-a Berlin-Frankfurt-Munster group report. Br J Haematol 2006; 133:176-182.
4. Rujkijyanont P, Morris C, Kang G, et al. Risk-adapted donor lymphocyte infusion based on chimerism and donor source in pediatric leukemia. Blood Cancer J 2013; 3:e137.
5. Spitzer TR. Haploidentical stem cell transplantation: The always present but overlooked donor. Hematol Am Soc Hematol Educ Program 2005;390-395.
6. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339:1186-1193.
7. Gordon PR, Leimig T, Mueller I, et al. A large-scale method for T cell depletion: Towards graft engineering of mobilized peripheral blood stem cells. Bone Marrow Transplant 2002; 30:69-74.
8. Mavroudis D, Read E, Cottler-Fox M, et al. CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 1996; 88:3223-3229.
9. Leung W. Use of NK cell activity in cure by transplant. Br J Haematol 2011; 155:14-29.
10. Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001; 98:3192-3204.
11. Dahlke MH, Larsen SR, Rasko JE, et al. The biology of CD45 and its use as a therapeutic target. Leuk Lymphoma 2004; 45:229-236.
12. Dutton RW, Bradley LM, Swain SL. T cell memory. Annu Rev Immunol 1998; 16:201-223.
13. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: Function, generation, and maintenance. Annu Rev Immunol 2004; 22:745-763.
14. Chao N, Memory T. cells. Biol Blood Marrow Transplant 2008; 14:17-19.
15. Faint JM, Annels NE, Curnow SJ, et al. Memory T cells constitute a subset of the human CD8 + CD45RA+ pool with distinct phenotypic and migratory characteristics. J Immunol 2001; 167:212-220.
16. Jameson SC, Masopust D. Diversity in T cell memory: An embarrassment of riches. Immunity 2009; 31:859-871.
17. Chen BJ, Cui X, Sempowski GD, et al. Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease. Blood 2004; 103:1534-1541.
18. Anderson BE, McNiff J, Yan J, et al. Memory CD4+ T cells do not induce graft-versus-host disease. J Clin Invest 2003; 112:101-108.
19. Amrolia PJ, Muccioli-Casadei G, Huls H, et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 2006; 108:1797-1808.
20. Ciurea SO, Mulanovich V, Jiang Y, et al. Lymphocyte recovery predicts outcomes in cord blood and T cell-depleted haploidentical stem cell transplantation. Biol Blood Marrow Transplant 2011; 17:1169-1175.
21. Bleakley M, Heimfeld S, Jones LA, et al. Engineering human peripheral blood stem cell grafts that are depleted of naive T cells and retain functional pathogen-specific memory T cells. Biol Blood Marrow Transplant 2014.
22. Teschner D, Distler E, Wehler D, et al. Depletion of naive T cells using clinical grade magnetic CD45RA beads: A new approach for GVHD prophylaxis. Bone Marrow Transplant 2013; 49:138-144.
23. Baird K, Fry TJ, Steinberg SM, et al. Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomas. Biol Blood Marrow Transplant 2012; 18:698-707.
24. Shook DR, Triplett BM, Srinivasan A, et al. Successful allogeneic hematopoietic cell engraftment after a minimal conditioning regimen in children with relapsed or refractory solid tumors. Biol Blood Marrow Transplant 2013; 19:291-297.
25. Perez-Martinez A, Leung W, Munoz E, et al. KIR-HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors. Pediatr Blood Cancer 2009; 53:120-124.
26. Lanzavecchia A, Sallusto F. Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. Science 2000; 290:92-97.
27. Novitzky N, Davison GM. Immune reconstitution following hematopoietic stem-cell transplantation. Cytotherapy 2001; 3:211-220.
28. Chen X, Hale GA, Barfield R, et al. Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies. Br J Haematol 2006; 135:524-532.
29. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333:1038-1044.
30. Leen AM, Christin A, Myers GD, et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood 2009; 114:4283-4292.
31. Perruccio K, Tosti A, Burchielli E, et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005; 106:4397-4406.
32. Klingebiel T, Handgretinger R, Lang P, et al. Haploidentical transplantation for acute lymphoblastic leukemia in childhood. Blood Rev 2004; 18:181-192.
33. Or R, Hadar E, Bitan M, et al. Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation. Biol Blood Marrow Transplant 2006; 12:1295-1301.
34. Lewalle P, Triffet A, Delforge A, et al. Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study. Bone Marrow Transplant 2003; 31:39-44.
35. Huang XJ. Current status of haploidentical stem cell transplantation for leukemia. J Hematol Oncol 2008; 1:27.
36. Distler E, Bloetz A, Albrecht J, et al. Alloreactive and leukemia-reactive T cells preferentially derive from naive precursors in healthy donors: Implications for immunotherapy with memory T cells. Haematologica 2011.
37. Morice A, Charreau B, Neveu B, et al. Cross-reactivity of herpesvirus-specific CD8 T cell lines toward allogeneic class I MHC molecules. PLoS ONE 2010; 5:e12120.
38. Elkington R, Khanna R. Cross-recognition of human alloantigen by cytomegalovirus glycoprotein-specific CD4+ cytotoxic T lymphocytes: Implications for graft-versus-host disease. Blood 2005; 105:1362-1364.
39. Melenhorst JJ, Scheinberg P, Williams A, et al. Alloreactivity across HLA barriers is mediated by both naive and antigen-experienced T cells. Biol Blood Marrow Transplant 2011; 17:800-809.
40. Burrows SR, Khanna R, Burrows JM, et al. An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: Implications for graft-versus-host disease. J Exp Med 1994; 179:1155-1161.
41. Handgretinger R, Klingebiel T, Lang P, et al. Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant 2001; 27:777-783.
42. Rebello P, Cwynarski K, Varughese M, et al. Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy 2001; 3:261-267.
43. Buggins AG, Mufti GJ, Salisbury J, et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood 2002; 100:1715-1720.
44. Chakraverty R, Orti G, Roughton M, et al. Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: Pharmacokinetics, GVHD, and immune reconstitution. Blood 2010; 116:3080-3088.
45. Morris EC, Rebello P, Thomson KJ, et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: Relevance for early adoptive immunotherapy and infectious complications. Blood 2003; 102:404-406.
46. Shah AJ, Kapoor N, Crooks GM, et al. The effects of Campath 1H upon graft-versus-host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants. Biol Blood Marrow Transplant 2007; 13:584-593.
47. Angiolillo AL, Yu AL, Reaman G, et al. A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: A children's oncology group report. Pediatr Blood Cancer 2009; 53:978-983.
48. Cutler C, Antin JH. Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 34 471-476.
49. Pidala J, Kim J, Anasetti C. Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009; 15:881-885.
50. Abouelnasr A, Roy J, Cohen S, et al. Defining the role of sirolimus in the management of graft-versus-host disease: From prophylaxis to treatment. Biol Blood Marrow Transplant 2013; 19:12-21.
51. Pulsipher MA, Wall DA, Grimley M, et al. A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). Br J Haematol 2009; 147 691-699.
52. Dancey J. MTOR signaling and drug development in cancer. Nat Rev Clin Oncol 2010; 7:209-219.
53. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 50:799-805.
54. Spunt SL, Grupp SA, Vik TA, et al. Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors. J Clin Oncol 2011; 29:2933-2940.
55. Hale GA, Arora M, Ahn KW, et al. Allogeneic hematopoietic cell transplantation for neuroblastoma: The CIBMTR experience. Bone Marrow Transplant 2013.
56. Thiel U, Wawer A, Wolf P, et al. No improvement of survival with reduced-versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. Ann Oncol 2011.